Review
Chemistry, Medicinal
Anand-Krishna Singh, Dhananjay Yadav, Neha Sharma, Jun-O Jin
Summary: Type 2 diabetes mellitus is characterized by high blood sugar levels, and therapeutic approaches include improving insulin sensitivity and using DPP-IV inhibitors. These inhibitors improve hyperglycemia by stabilizing gut hormones such as glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptides.
Article
Endocrinology & Metabolism
Andrea Kelly, Saba Sheikh, Darko Stefanovski, Amy J. Peleckis, Sarah C. Nyirjesy, Jack N. Eiel, Aniket Sidhaye, Russell Localio, Robert Gallop, Diva D. De Leon, Denis Hadjiliadis, Ronald C. Rubenstein, Michael R. Rickels
Summary: In this study, it was found that the use of sitagliptin in glucose intolerant PI-CF patients increased levels of incretin hormones, improved early insulin secretion and glucagon suppression, but did not affect glucose tolerance or beta-cell sensitivity to glucose.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Andrea Kelly, Saba Sheikh, Darko Stefanovski, Amy J. Peleckis, Sarah C. Nyirjesy, Jack N. Eiel, Aniket Sidhaye, Russell Localio, Robert Gallop, Diva D. De Leon, Denis Hadjiliadis, Ronald C. Rubenstein, Michael R. Rickels
Summary: In this study, DPP-4 inhibitor sitagliptin was found to increase meal-related incretin responses, improve early insulin secretion and glucagon suppression in pancreatic insufficient cystic fibrosis (PI-CF) patients with abnormal glucose tolerance. However, there were no significant improvements in glucose tolerance or beta-cell sensitivity to glucose after 6 months of treatment with sitagliptin compared to placebo.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Chemistry, Medicinal
Baljit Kaur, Sombir Jaglan, Sudesh Rani, Yatin Batra, Palwinder Singh, Palwinder Vivesh
Summary: This study reports the design, synthesis, and biological studies of new anti-diabetic agents targeting DPP-4. The results show that 14 compounds display better inhibition activity against DPP-4 than the known drug Sitagliptin.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2022)
Article
Biology
Szymon Jonik, Michal Marchel, Marcin Grabowski, Grzegorz Opolski, Tomasz Mazurek
Summary: This manuscript provides a comprehensive summary of the role of gastrointestinal hormones GIP and GLP-1 in atherosclerosis and coronary artery disease. The study suggests that GIP and GLP-1 are expressed in various human tissues and are associated with inflammation, atherosclerosis, and myocardial ischemia. In animal models, GIP and GLP-1 improve endothelial function and reduce macrophage infiltration in atherosclerotic plaques. In humans, GIP and GLP-1 have both pro-atherosclerotic and anti-atherosclerotic effects. Clinical trials have shown that GLP-1 analogs can significantly reduce cardiovascular events in patients with type 2 diabetes. However, more research is needed to understand the metabolism of GIP in acute myocardial ischemia and stable coronary artery disease.
Article
Sport Sciences
Yung-Chih Chen, Jean-Philippe Walhin, Aaron Hengist, Javier T. Gonzalez, James A. Betts, Dylan Thompson
Summary: Interrupting prolonged sitting with intermittent walking can increase postprandial GLP-1 and PYY concentrations in healthy middle-age men and women with central adiposity.
MEDICINE & SCIENCE IN SPORTS & EXERCISE
(2022)
Article
Food Science & Technology
Wei Wang, Xiaoqing Liu, Yiju Li, Haixi You, Zhipeng Yu, Liying Wang, Xuebo Liu, Long Ding
Summary: In this study, different enzymes and simulated digestion were used to investigate the DPP-IV inhibitory activities of oat protein hydrolysates. Neutrase was found to produce oat protein hydrolysate with the most potent DPP-IV inhibitory property, and ten new DPP-IV inhibitory peptides were identified. Molecular docking experiments further confirmed the interaction between these peptides and DPP-IV. Therefore, oat could be a promising source of dietary supplement for type 2 diabetes mellitus (T2DM).
Article
Endocrinology & Metabolism
Ryan J. Jalleh, Laurence G. Trahair, Tongzhi Wu, Scott Standfield, Christine Feinle-Bisset, Christopher K. Rayner, Michael Horowitz, Karen L. Jones
Summary: This study aimed to evaluate the effect of gastric distension on the secretion of GIP and GLP-1 in healthy individuals. The results showed that gastric distension did not significantly stimulate the secretion of GLP-1 and GIP, regardless of the presence or absence of small intestinal nutrients.
DIABETES OBESITY & METABOLISM
(2023)
Review
Medicine, Research & Experimental
Akira Mima, Atsuo Nomura, Takeshi Fujii
Summary: Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and is considered one of the most significant complications of diabetes. Incretin-based therapies, such as GLP-1 receptor agonists and DPP-4 inhibitors, have shown potential in reducing DKD. While GIP has been considered unsuitable for type 2 diabetes treatment in the past, recent studies have demonstrated its possible efficacy with improved glycemic control. Novel dual- or triple-receptor agonists that target GLP-1, GIP, and glucagon receptors are being developed to address multiple metabolic pathways in type 2 diabetes.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Editorial Material
Endocrinology & Metabolism
Hirotaka Araki, Takeshi Matsumura, Noboru Furukawa, Eiichi Araki
Summary: This article explores the mechanisms of dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor dual-agonists in glycemic control and/or weight loss.
JOURNAL OF DIABETES INVESTIGATION
(2023)
Article
Medicine, General & Internal
Soyeon Yoo, Dongkyu Kim, Gwanpyo Koh
Summary: The study investigated changes in glucagon levels in people with diabetes after meal ingestion, finding that poorly controlled patients may have a greater increase in postprandial glucagon levels, which is not mediated by incretin.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Henrik H. Hansen, Rikke Gronlund, Tamara Baader-Pagler, Peter Haebel, Harald Tammen, Leif Kongskov Larsen, Jacob Jelsing, Niels Vrang, Thomas Klein
Summary: DPP-IV inhibitors improve glycemic control by prolonging the action of GLP-1, while Y2R-selective agonists induce significant weight loss. In combination therapy, potential negative modulatory effects of DPP-IV inhibitors on endogenous Y2R peptide agonist activity do not seem sufficient to influence weight homeostasis.
SCIENTIFIC REPORTS
(2021)
Article
Chemistry, Analytical
Jiemin Wang, Liang Zhang, Yi Qu, Yuexia Yang, Ting Cao, Yuping Cao, Anam Iqbal, Wenwu Qin, Yun Liu
Summary: A fluorescent probe named DCDHFNH2-dpp4 has been designed for detecting diabetes, showing promising results in mice models, especially with high specificity for diabetic mice. This probe also exhibits significant fluorescence signals in the liver and serum of diabetic mice.
ANALYTICAL CHEMISTRY
(2021)
Article
Endocrinology & Metabolism
Shiau Chin Chong, Norlela Sukor, Sarah Anne Robert, Kim Fong Ng, Nor Azmi Kamaruddin
Summary: This study assessed the impact of endogenous GLP-1 levels on the treatment response to DPP-IV inhibitors in individuals with prediabetes and T2D. The results showed that linagliptin significantly reduced HbA1c and glucose levels in individuals with high GLP-1 levels. This suggests that endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV inhibitors.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Immunology
Gaber El-Saber Batiha, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Nada A. Ashour, Walaa A. Negm
Summary: In Covid-19 patients, variations in fasting blood glucose are considered a distinct risk factor for a negative prognosis. Tirazepatide (TZT), a dual GLP-1 and GIP receptor agonist, may be effective in managing Covid-19-induced hyperglycemia in both diabetic and non-diabetic patients.
INFLAMMOPHARMACOLOGY
(2023)
Article
Cell Biology
Kirsten Hattermann, Kareen Bartsch, Henrike H. Gebhardt, H. Maximilian Mehdorn, Michael Synowitz, Anne Dorothee Schmitt, Rolf Mentlein, Janka Held-Feindt
CELL COMMUNICATION AND SIGNALING
(2016)
Article
Ophthalmology
Michaela Dithmer, Kirsten Hattermann, Prasti Pomarius, Shereen Hassan Aboul Naga, Tim Meyer, Rolf Mentlein, Johann Roider, Alexa Klettner
EXPERIMENTAL EYE RESEARCH
(2016)
Article
Oncology
Kirsten Hattermann, Charlotte Flueh, Dorothee Engel, H. Maximilian Mehdorn, Michael Synowitz, Rolf Mentlein, Janka Held-Feindt
INTERNATIONAL JOURNAL OF ONCOLOGY
(2016)
Article
Biology
Kirsten Hattermann, Henrike Gebhardt, Sebastian Krossa, Andreas Ludwig, Ralph Lucius, Janka Held-Feindt, Rolf Mentlein
Review
Anatomy & Morphology
Kirsten Hattermann, Rolf Mentlein
ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER
(2013)
Article
Cell Biology
Kirsten Hattermann, Eric Holzenburg, Friederike Hans, Ralph Lucius, Janka Held-Feindt, Rolf Mentlein
CELL AND TISSUE RESEARCH
(2014)
Article
Oncology
Janka Held-Feindt, Kirsten Hattermann, Susanne Sebens, Stefan Krautwald, H. Maximilian Mehdorn, Rolf Mentlein
EXPERIMENTAL CELL RESEARCH
(2013)
Article
Ophthalmology
Christin Hettich, Sebastian Wilker, Rolf Mentlein, Ralph Lucius, Johann Roider, Alexa Klettner
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2014)
Article
Critical Care Medicine
Sebastian Lippross, Tim Klueter, Nadine Steubesand, Stefanie Oestern, Rolf Mentlein, Frank Hildebrandt, Rainer Podschun, Thomas Pufe, Andreas Seekamp, Deike Varoga
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
(2012)
Article
Immunology
Kirsten Hattermann, Janka Held-Feindt, Andreas Ludwig, Rolf Mentlein
JOURNAL OF NEUROIMMUNOLOGY
(2013)
Article
Cell Biology
Tim Klueter, Stefanie Fitschen-Oestern, Sebastian Lippross, Matthias Weuster, Rolf Mentlein, Nadine Steubesand, Claudia Neunaber, Frank Hildebrand, Thomas Pufe, Mersedeh Tohidnezhad, Andreas Beyer, Andreas Seekamp, Deike Varoga
MEDIATORS OF INFLAMMATION
(2014)
Article
Oncology
Gu Li, Kirsten Hattermann, Rolf Mentlein, H. Maximilian Mehdorn, Janka Held-Feindt
Article
Oncology
Kirsten Hattermann, Susanne Sebens, Ole Helm, Anne Dorothee Schmitt, Rolf Mentlein, H. Maximilian Mehdorn, Janka Held-Feindt
Article
Cell Biology
Kirsten Hattermann, Gu Li, Heinz-Hermann Hugo, Rolf Mentlein, H. Maximilian Mehdorn, Janka Held-Feindt
HISTOLOGY AND HISTOPATHOLOGY
(2013)
Article
Ophthalmology
Julia Dieckow, Wolfgang Brandt, Kirsten Hattermann, Stefan Schob, Ute Schulze, Rolf Mentlein, Philipp Ackermann, Saadettin Sel, Friedrich P. Paulsen
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
(2016)